L-Carnitine for Fatigue

Verdict: Weak, population-specific evidence; not a general fatigue fix

L-carnitine is not a reliable remedy for everyday fatigue. The strongest evidence shows no benefit for cancer-related fatigue, and the few positive trials are limited to specific older or disease-affected groups who may have been carnitine-deficient.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This earns a Weak (C) grade because the evidence is mixed and highly population-dependent rather than supportive of broad use. The largest and highest-quality trial, a 376-patient double-blind RCT (PMID 22987089), found no benefit over placebo for cancer-related fatigue, and a systematic review and meta-analysis (PMID 29112178) agreed, reporting a negligible effect (SMD 0.06; p=0.45). These are the most rigorous data available, and they are null.

Positive results exist only in narrow groups: centenarians (PMID 18065594), elderly patients (PMID 17658628), prefrail older adults (PMID 27895474), and people with hepatic encephalopathy (PMID 21310833). These trials were small, often did not disclose funding, and used populations prone to carnitine deficiency, so the improvement likely reflects correcting a deficit rather than a general anti-fatigue effect. The hepatic encephalopathy benefit may also be confounded by falling ammonia levels.

Regulators and clinicians reinforce caution. The US FDA treats L-carnitine only as a nutrient supplement, the EU's EFSA has rejected related health claims, and the Mayo Clinic states it is not recommended for MS-related fatigue. No authority endorses it for fatigue, and for cancer-related fatigue guideline bodies favor exercise as first-line care. Adequately powered trials in healthy adults are essentially absent.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.448
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

L-carnitine supplementation for the management of fatigue in patients with cancer: an ECOG phase III
PMID: 22987089 2012 RCT (double-blind) n = 376
Finding: No significant difference vs placebo in reducing cancer-related fatigue (p=0.57); both groups improved equally.
🟢 High quality Government
View on PubMed
Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis
PMID: 29112178 2017 系統性回顧 n = 3
Finding: Carnitine did not significantly reduce cancer-related fatigue; SMD=0.06 (95% CI -0.09, 0.21; p=0.45). Higher-quality studies do not support use.
Effect size: SMD 0.06 (95% CI -0.09 to 0.21)
View on PubMed
Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study
PMID: 21310833 2011 RCT (double-blind) n = 121
Finding: Significant reduction in fatigue severity in both HE groups vs placebo (FSS -6.4 vs +2.3, p<0.001; FSS -8.1 vs -5.1, p<0.001); ammonia also decreased significantly.
Academic Effect size: FSS MD ~8.7 (HE1 group); FSS MD ~3.0 (HE2 group)
View on PubMed
L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians
PMID: 18065594 2007 RCT (double-blind) n = 66
Finding: Significant improvement in mental fatigue (-2.70 vs +0.30, p<0.001) and fatigue severity (-23.60 vs +1.90, p<0.001) in centenarians.
Effect size: FSS MD ~25.5 vs placebo
View on PubMed
Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue
PMID: 17658628 2008 RCT (double-blind) n = 96
Finding: Physical fatigue decreased by 7 points (p<0.0001) vs -0.5 in controls; mental fatigue -3.3 (p<0.0001) vs +0.6; FSS -22.5 (p<0.0001) vs +1.2.
Effect size: FSS MD ~23.7 vs placebo
View on PubMed
Efficacy of L-carnitine supplementation on frailty status and its biomarkers, nutritional status, and physical and cognitive function among prefrail older adults
PMID: 27895474 2016 RCT (double-blind) n = 50
Finding: Frailty Index and grip strength improved significantly (p<0.05); authors conclude favorable effect on fatigue in prefrail elderly.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
NUTRIENT SUPPLEMENT source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
膠囊狀、錠狀且標示有每日食用限量之食品,在每日食用量中,L-肉鹼(L-肉酸)總含量不得高於2克。特殊營養食品得視實際需要適量使用。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Research hasn't proven that acetyl-L-carnitine helps MS-related fatigue. At this time it isn't recommended for treating MS-related fatigue. source↗
L5c Cleveland Clinic
Not addressed
L5e Specialty Society (condition-mapped)
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-fatigue-INT-l-carnitine-001 繁體中文版 →